The differential intracellular expression of the novel marker ATF-3 characterizes the quiescent or activated state of endogenous spinal stem cells: a tool to study neurorepair? by Mladinic, M. & Nistri, A.
The Differential Intracellular Expression of the Novel Marker ATF-3
Characterizes the Quiescent or Activated State of Endogenous Spinal Stem Cells:
A Tool to Study up Neurorepair?
Miranda Mladinic1,2* and Andrea Nistri2
1Department of Biotechnology, University of Rijeka, Rijeka, Croatia
2Neuroscience Department, International School for Advanced Studies (SISSA), Trieste, Italy
*Corresponding author: Miranda Mladinic, Associate Professor, Department of Biotechnology, University of Rijeka, Rijeka, Croatia, Tel: 385 51 584567; E-mail: 
mirandamp@uniri.hr
Rec date: May 19, 2014, Acc date: May 23, 2014, Pub date: May 30, 2014
Copyright: © 2014 Mladinic M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Editorial
Worldwide, spinal cord injury (SCI) remains a major cause of
disability with serious consequences in terms of personal and social
costs [1]. Thus, important issues are how to protect the spinal cord to
limit its initial damage, how to repair a lesion, and how to facilitate
recovery by exploiting surviving tissue. These needs are currently
unmet because our knowledge of the detailed structure of the neuronal
networks responsible for human locomotion is scanty and our control
over the mechanisms involved in neuronal death and regeneration is
very limited. The molecular mechanisms underlying neuronal death
after SCI are incompletely understood so that specific strategies for
neuroprotection remain preliminary [2-4]. While many
neuroprotective molecules have been reported to be experimentally
effective for neuronal survival after SCI, very few have reached the
clinical testing stage and none of them has provided efficacious
treatment for SCI patients [5]. The reasons for such a clinical failure
are complex and may include the diversity of protocols used to induce
injury in animal models and the difficulty of detailed animal tissue
analysis beyond a single time point so that a relatively narrow window
of pathophysiology may be explored [6,7]. In clinical settings, the large
majority of SCI cases are managed at late stages after the patient’s
conditions have been stabilized following the primary lesion. Hence,
damage repair rather than neuroprotection becomes a crucial goal.
Exogenous stem cells for SCI therapy
In the mammalian central nervous system, lesioned neurons often
do not regrow axons and, even if they might be induced to sprout
fibers, they fail to re-innervate strategic network targets. Furthermore,
because surviving cells do not replace or substitute dead postmitotic
neurons, a neurodegenerative scenario is progressively established.
Within this framework of SCI studies, recent therapeutic strategies
have mostly focused on repair mechanisms using stem cells [8,9]. One
approach is to transplant embryonic or adult stem/progenitor cells
(with or without prior manipulation ex vivo) into the site of spinal
cord damage [10-13]. These studies have shown that stem cells might
provide trophic and immunomodulatory factors to the injured spinal
cord tissue, and may, thus, enhance axonal growth, remyelination of
spared axons (by newly formed oligodendrocytes) and contrast
neuroinflammation [1]. Even though generation of new neurons has
been reported [14,15], the idea that these cells will replace dead
neurons and integrate within neuronal circuits remains, however, a
conjecture only [1]. The common problems inherent to
transplantation-based strategies, namely the risk of immune rejection
and the need for an external source of cells with related ethical
concerns, were recently addressed by generating autologous
pluripotent stem cells from the skin fibroblasts manipulated with viral
vectors [16]. These preliminary results need careful longitudinal
studies to validate their safety especially in terms of cancerogenic
potential.
There is, at present, an intense debate on the challenges to
successful translation of promising cellular therapies and approaches
from the experimental preclinical studies to clinically efficacious
treatment for patients [17]. Details of the clinical studies in which SCI
patients received different types of stem cell have recently been
described [18,19]. Unfortunately, there is no fully documented
functional benefit for the majority of the SCI patients recruited in such
trials.
In particular, the first clinical trial was run by Geron USA with
transplantation of human embryonic-derived oligodendrocyte
progenitor cells. This study was approved by the FDA against a
background of controversy regarding the ethical and safety concerns
(formation of teratoma). Nevertheless, while the safety of the
procedure was shown, no neurological recovery of the patients was
obtained so that the trial was abruptly stopped [18,19]. Transplanting
olfactory ensheating glial cells, which offer the possibility of
autologous transplantation, has confirmed the safety of this procedure
in clinical trials without, however, providing documented motor
improvement [19,20]. Likewise, even though transplantation of bone
marrow derived mesenchymal stem cells has shown promising results
in preclinical studies on animals (rats, pigs, non-human primates)
with improved locomotor performance, this procedure has failed to
show functional benefit to SCI patients in several small cohort studies
[19]. Despite the fact that Schwann cells have long been investigated in
preclinical transplantation research, very few clinical trials with SCI
patients have been performed: one small trial completed after
autologous transplantation, has shown the safety of the procedure,
with no data on functional outcome [19,21].
The positive results obtained in animal studies using neural stem
cells isolated from embryonic or adult spinal cord and brain, have
encouraged translational studies using human central nervous system
stem cells (HuCNS-SC). While this work started in 2011 in
Switzerland and was sponsored by StemCells Inc, its results have not
yet been published [19]. New hopes for transplantation strategies
come from induced pluripotent stem cells that share many
characteristics with embryonic stem cells, thus, allowing autologous
transplantation to circumvent ethical concerns. Future studies are
needed for their safety (teratoma induction?) and usefulness to SCI
patients. Even though more pre-clinical studies with other types of
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stem cell, like for example umbilical cord and adipose derived
mesenchymal stem cells are required, two clinical trials have been
already concluded or are in progress in Korea, with no data about the
outcome [19].
Endogenous spinal stem cells
Activating the endogenous stem cells normally present in the
mammalian spinal cord could represent a valid alternative to stem cell
transplantation strategy after injury, since this is a non-invasive
method that does not require immune suppression [22]. Indeed, in
lower vertebrates, which can completely and spontaneously recover
after SCI, endogenous spinal stem cells play a major role in the spinal
cord regeneration process [23]. The mammalian spinal cord niches
containing stem and progenitor cells capable of adult neurogenesis
have been less investigated than those in the subventicular zone of the
lateral ventricles of the forebrain, and in the subgranular zone of the
dentate gyrus of the hippocampus [24]. The neural stem cells potential
in the adult mammalian caudal nervous system resides mainly within
the population of ependymal cells lining the spinal central canal [25].
Here, several cell types reside with different morphology, location,
function and specific markers (ependymocytes, tanycytes, cerebral-
fluid contacting neurons, etc.), plus a pool of stem and progenitor cells
readily activated and recruited after experimental spinal damage [23].
Even though their sustained adult neurogenesis was not observed
[23,26], the neural stem cells present in the adult spinal cord are
recruited and proliferate after SCI [27] to produce scar-forming
astrocytes and myelinating oligodendrocytes [22]. They can also be
pharmacologically (with growth factors) and genetically manipulated
to stimulate neurogenesis and oligodendrogenesis [28]. Recent reports
have indicated an important role of spinal endogenous stem cells in
restricting the tissue damage and neural loss after injury through the
formation of glial scar and exerting the neurotrophic effect required
for survival of neurons adjacent to the lesion [29].
Although spinal cord endogenous stem/progenitor cells represent a
potential source for future SCI treatments, there is the immediate need
to fully identify them prior to any manipulation for their recruitment
after injury. Spinal stem/progenitor cells are especially difficult to
identify due to their heterogeneity as well as lack of specific
expressional markers, since the ones currently in use significantly
overlap with those of mature astrocytes [30]. In addition, there is no
specific marker to discriminate between quiescent and activated
ependymal spinal cells, nor any one capable of monitoring their
migration and differentiation after injury. Furthermore, the signalling
pathways and genes that control the fate of the spinal cord stem/
progenitor cells in normal and pathological situations, are largely
unknown [23]. In fact, the transcription factors controlling spinal cord
stem cells should be extensively studied because to date they have been
investigated with in vitro primary cultures only [27] and their
applicability to the in vivo tissue remains to be tested.
One important contribution to this field may come from in vitro
spinal cord injury models, in which the basic molecular mechanisms
involved in the death, survival and regeneration of neurons after SCI
can be investigated at preselected time points and useful correlations
between damage and loss of locomotor network function can be
obtained [3,31].
In the course of the studies trying to reveal basic molecular
mechanisms involved in the pathophysiology of the SCI using the in
vitro spinal cord preparation, activation of spinal stem/progenitor cells
(positive for stem/progenitor cells markers such as nestin, vimentin or
the SOX2 transcription factor) is observed in association with their
migration from the ependymal region surrounding a central canal
toward the ventral and dorsal funiculi. This pattern is largely
reminiscent of the rostral migratory stream of brain subventricular
stem cells [32] (Figure 1).
Figure 1: On the left panel the 30 μm thick section of the neonatal
rat spinal cord has been stained with the nuclear dye DAPI (4',6-
diamidino-2-phenylindole) to visualise nuclei of spinal cells. The
region marked with the red dashed line is shown at higher
magnification in the right panel. Right: the region around the
central canal of the spinal cord (CC) has been labelled with a
fluorescent antibody to visualise the Activating transcription factor
3 (ATF3; green) or to observe the incorporation of EdU (5-
ethynyl-2'-deoxyuridine) into proliferating cells (red). The ATF3 is
expressed in the nuclei of the activated spinal cord stem/progenitor
cells that migrate from the ependymal zone around the spinal cord
central canal versus dorsal and ventral funiculi, in a cell formation
called funicular migratory stream (FMS). Proliferating cells that are
also ATF3 positive are shown in yellow. (unpublished data by M.
Mladinic and A. Dekanic).
Both quiescent and migrating spinal stem/progenitor cells express
the Activating transcription factor 3 (ATF3), which currently has no
clear role in neuronal development of the intact nervous system, and
its expression has not been previously reported in any type of stem/
progenitor cell. ATF3 belongs to the mammalian ATF/cAMP
responsive element-binding (CREB) protein family of the Basic
Leucine Zipper (bZIP) transcription factors [33] and is thought to be a
stress inducible gene and an adaptive response gene, which, when
activated by various stimuli, can control cell cycle and cell death
machinery [34]. Although ATF3 expression is normally very low in
central nervous system, it is markedly upregulated in response to
injury and closely linked to survival and regeneration of peripheral
axons [34]. ATF3 is supposed to have a role in neurite growth and
regeneration [35] and it has been identified as regulator of neuronal
survival against excitotoxic and ischemic brain damage [36,37].
It is particularly interesting that ATF3 expression in spinal
ependymal stem/progenitor cells is dynamic, as this protein is
localized to the cytoplasm of such cells when they are quiescent, and it
Citation: Mladinic M, Nistri A (2014) The Differential Intracellular Expression of the Novel Marker ATF-3 Characterizes the Quiescent or Activated
State of Endogenous Spinal Stem Cells: A Tool to Study up Neurorepair?. J Spine 3: e113. doi:10.4172/2165-7939.1000e113
Page 2 of 4
J Spine
ISSN:2165-7939 JSP, an open access journal Volume 3 • Issue 3 • 1000e113
is detected in the nucleus when cells became activated [32] (Figure 1).
This discovery opens the new possibility to track down migrating
spinal stem/progenitor cells after injury and to identify the molecules
that control their activation (for example miRNA differentially
expressed in quiescent versus migrating ependyma-derived cells).
Furthermore, the nuclear ATF3 expression in migrating spinal stem/
progenitor cells gives the possibility to monitor their translocation and
differentiation (versus neuronal or glial cell lineages) after injury.
Although future studies have to decipher the role of ATF3 in spinal
stem/progenitor cell maintenance and mobilization, the identification
of ATF3 as a unique marker to distinguish between quiescent and
migrating spinal endogenous stem/progenitor cells can help
characterizing those factors that control their activation and fate after
injury, and might become a reporter molecule in studies of drug
testing for SCI outcome.
Conclusion
The former disappointing results from clinical studies exploring
neurorepair strategies to restore neuronal connectivity in the networks
that underlie standing and walking, should stimulate novel approaches
aimed at exploiting the endogenous rewiring potential of the
ependymal stem/progenitor cells. These goals demand precise basic
knowledge of their niche topography, their transcriptional potential,
metabolism, and physiology. Thus, in the future, full genomic and
functional characterization of these cells should provide new
opportunities to control their migration toward the lesion sites and
their neuronal differentiation.
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